Chemotherapy Research and Practice

Monoclonal Antibodies against Epidermal Growth Factor Receptor in Solid Tumors


Publishing date
31 Aug 2012
Status
Published
Submission deadline
13 Apr 2012

Lead Editor

1Department of Hematology and Medical Oncology, Emory University, Atlanta, GA 30322, USA

2Department of Radiation Oncology, University of California, San Francisco, CA 94143, USA

3Department of Medicine, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY 10461, USA

3Department of Hematology and Medical Oncology, Emory University, Atlanta, GA 30322, USA


Monoclonal Antibodies against Epidermal Growth Factor Receptor in Solid Tumors

Description

The epidermal-growth-factor-receptor- (EGFR-) driven pathways seem to affect the growth and behavior of a significant number of solid tumors. Monoclonal antibodies to EGFR and small-molecule inhibitors of the tyrosine kinase activity of the EGFR receptor are two classes of anticancer agents that inhibit EGFR. Anti-EGFR monoclonal antibodies therapies have been approved in the treatment of several types of solid tumors such as squamous cell carcinoma of the head and neck (SCCHN), colorectal cancer, and breast cancer and have been extensively studied in other malignancies such as lung cancer and esophageal cancer.

We invite investigators to contribute original research articles as well as review articles that will cover preclinical studies exploring EGFR signaling and mechanisms of resistance and using EGFR monoclonal antibodies. Review papers covering the optimal use of these agents in treating a variety of solid tumors are also welcome. Potential topics include, but are not limited to:

  • The epidermal growth factor receptor: the rationale for targeting and treatment strategies
  • Monoclonal antibodies to EGFR: preclinical models
  • Monoclonal antibodies to EGFR: phase I studies
  • Monoclonal antibodies to EGFR: studies in lung cancer
  • Monoclonal antibodies to EGFR: studies and guidelines in squamous cell carcinoma of the head and neck cancer
  • Mechanisms of resistance to EGFR antibodies
  • Monoclonal antibodies to EGFR: applications in colorectal cancer
  • Monoclonal antibodies to EGFR: studies in breast cancer
  • Overview of anti-Her-2 therapy: present and future
  • Molecular predictors of response to EGFR monoclonal antibodies and future strategies

Before submission authors should carefully read over the journal's Author Guidelines, which are located at http://www.hindawi.com/journals/chrp/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/ according to the following timetable:


Articles

  • Special Issue
  • - Volume 2012
  • - Article ID 291421
  • - Editorial

Monoclonal Antibodies against Epidermal Growth Factor Receptor in Solid Tumors

Nabil F. Saba | Sue S. Yom | ... | Bassel El-Rayes
  • Special Issue
  • - Volume 2012
  • - Article ID 743193
  • - Review Article

The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy

Zahi Mitri | Tina Constantine | Ruth O'Regan
  • Special Issue
  • - Volume 2012
  • - Article ID 817304
  • - Review Article

Advances in Targeting HER3 as an Anticancer Therapy

Ning Jiang | Nabil F. Saba | Zhuo Georgia Chen
  • Special Issue
  • - Volume 2012
  • - Article ID 387172
  • - Review Article

Novel Drugs Targeting the Epidermal Growth Factor Receptor and Its Downstream Pathways in the Treatment of Colorectal Cancer: A Systematic Review

Amartej Merla | Sanjay Goel
  • Special Issue
  • - Volume 2012
  • - Article ID 198197
  • - Review Article

Antiepidermal Growth Factor Receptor Monoclonal Antibodies: Applications in Colorectal Cancer

Efat Azizi | Adam Kittai | Peter Kozuch
  • Special Issue
  • - Volume 2012
  • - Article ID 761518
  • - Review Article

The Use of Epidermal Growth Factor Receptor Monoclonal Antibodies in Squamous Cell Carcinoma of the Head and Neck

Jeffery S. Russell | A. Dimitrios Colevas
  • Special Issue
  • - Volume 2012
  • - Article ID 901320
  • - Review Article

EGFR Monoclonal Antibodies in the Treatment of Squamous Cell Carcinoma of the Head and Neck: A View beyond Cetuximab

Scott A. Kono | Missak Haigentz | ... | Nabil Saba
  • Special Issue
  • - Volume 2012
  • - Article ID 351210
  • - Review Article

Dermatologic Toxicities from Monoclonal Antibodies and Tyrosine Kinase Inhibitors against EGFR: Pathophysiology and Management

Shaad E. Abdullah | Missak Haigentz | Bilal Piperdi
  • Special Issue
  • - Volume 2012
  • - Article ID 817297
  • - Review Article

Mechanisms of Resistance to Epidermal Growth Factor Receptor Inhibitors and Novel Therapeutic Strategies to Overcome Resistance in NSCLC Patients

Luping Lin | Trever G. Bivona
  • Special Issue
  • - Volume 2012
  • - Article ID 648965
  • - Review Article

Deciphering the Role of Insulin-Like Growth Factor-I Receptor in Trastuzumab Resistance

Rita Nahta